Antiparasitics: Products and markets

Antiparasitics: Products and markets

NEW ground-breaking antiparasitics research contained in this report!

If you are looking to expand your antiparasitics business, enter the antiparasitics market, or move into a new geographic market - this report is for you. The antiparasitics sector has achieved dramatic growth in recent years, outpacing any other animal health product sector. This report brings together the latest issues and pressures within this dynamic area. It examines:

The increasing demand for NEW products that work
Geographic analysis of the major antiparasitics markets
The leading companies and new entrants
New research being carried out by companies in this product sector

It will show you the extent to which companies are moving away from conventional products and are turning to alternative product strategies. You can find out where leading companies in this dynamic sector are directing their R&D efforts.

Companies profiled: Merial; Pfizer; Bayer; Fort Dodge; Novartis; Schering-Plough; Hoechst Roussel Vet; Virbac; Phoenix Scientific; Ancare

Price: £450/$945/¥108,000
Published: June 1999
Pages: 130
Ref: SR186E

For further information about this report, please contact our Customer Helpdesk on:
Tel: +44 (0)20 8332 8965 / 66
Fax: +44 (0)20 8332 8992
E-mail: [email protected]

CONTENTS
LIST OF TABLES
LIST Of FIGURES
EXECUTIVE SUMMARY
ABBREVIATIONS AND EXCHANGE RATES

CHAPTER 1 MAJOR PARASITES
1.1 Parasites in cattle
1.1.1 Endoparasites
1.1.2 Ectoparasites
1.2 Major sheep and goat parasites
1.2.1 Endoparasites
1.2.2 Ectoparasites
1.3 Major pig parasites
1.3.1 Endoparasites
1.3.2 Ectoparasites
1.4 Major poultry parasites
1.4.1 Endoparasites
1.4.2 Ectoparasites
1.5 Major horse parasites
1.5.1 Endoparasites
1.5.2 Ectoparasites
1.6 Major cat and dog parasites
1.6.1 Endoparasites
1.6.2 Ectoparasites
1.7 Parasites in fish
1.7.1 Endoparasites
1.7.2 Ectoparasites
1.8 Major bee parasites
1.8.1 Acaricide resistance

CHAPTER 2 ANTIPARASITIC PRODUCTS
2.1 Ectoparasitics
2.1.1 Benzoyl urea derivatives
2.1.2 Pyrazoles
2.1.3 Nitroguanidines
2.1.4 Amidines
2.1.5 Insect growth regulators
2.1.6 Organophosphates
2.1.7 Carbamates
2.1.8 Pyrethrins and synthetic pyrethroids
2.1.9 Organochlorines
2.2 Endoparasitics
2.2.1 Benzimidazoles
2.2.2 Probenzimidazoles
2.2.3 Imidazothiazoles
2.2.4 Tetrahydropyrimidines
2.2.5 Salicylanilides
2.2.6 Organophosphates
2.2.7 Piperazines
2.2.8 Macrocyclic lactones
2.2.9 Other endoparasitics
2.3 Endectocides
2.3.1 Avermectins
2.3.2 Milbemycins
2.4 Poultry anticoccidials
2.4.1 Ionophore anticoccidial products
2.4.2 Chemical anticoccidial products
2.5 Vaccines
2.6 Generic competition
2.6.1 Generics in the US
2.6.2 Generics in Brazil
2.7 Parasite resistance
2.7.1 South America
2.7.2 The UK
2.7.3 Australia
2.7.4 Computer modelling
2.7.5 Resistance tests
2.7.6 Predicting resistance
2.8 Drug delivery methods
2.8.1 Endoparasitic and endectocide delivery systems
2.8.2 Ectoparasitic delivery systems
2.9 Organophosphate concerns
2.9.1 UK concerns
2.9.2 Australian concerns

CHAPTER 3 ANTIPARASITIC RESEARCH
3.1 New antiparasitics
3.1.1 Bayer
3.1.2 Merial
3.1.3 Pfizer
3.1.4 BTG
3.1.5 US Department of Agriculture
3.2 New vaccines
3.2.1 Vaccines for cats and dogs
3.2.2 Endoparasitic vaccines for livestock
3.2.3 Ectoparasitic vaccines for livestock
3.3 Alternative strategies
3.3.1 Blowfly-attacking enzymes
3.3.2 Nematode-eating fungi
3.3.3 Genetic markers for resistance
3.3.4 The Nemesis project
3.3.5 Nutrition
3.3.6 Bioclip
3.3.7 Trapping parasites
3.3.8 Reducing antiparasitic usage
3.3.9 Screwworm fly
3.3.10 Varroasis
3.3.11 Garlic

CHAPTER 4 THE ANTIPARASITICS MARKET
4.1 The world animal health market
4.2 The antiparasitics market
4.2.1 Ectoparasitics
4.2.2 Endoparasitics
4.2.3 Anticoccidials
4.2.4 Outlook for antiparasitics
4.3 Major national antiparasitic markets
4.3.1 The US
4.3.2 Brazil
4.3.3 France
4.3.4 The UK
4.3.5 Australia
4.3.6 Japan
4.3.7 Germany
4.3.8 Argentina
4.3.9 South Africa
4.3.10 China

CHAPTER 5 COMPANY PROFILES
5.1 Merial
5.1.1 Ivermectin
5.1.2 Heartgard
5.1.3 Eqvalan
5.1.4 Eprinomectin
5.1.5 Frontline
5.1.6 Future developments
5.2 Pfizer
5.2.1 Dectomax
5.2.2 Pyrantel-based products
5.2.3 Anticoccidials
5.2.4 Other products
5.2.5 Future developments
5.3 Bayer
5.3.1 Advantage
5.3.2 Other companion animal products
5.3.3 Livestock products
5.3.4 Sanvet
5.3.5 Future developments
5.4 Fort Dodge
5.4.1 Moxidectin
5.4.2 Oxfendazole
5.4.3 Vaccines
5.5 Novartis
5.5.1 Program
5.5.2 Other companion animal antiparasitics
5.5.3 Livestock products
5.5.4 Future developments
5.6 Schering-Plough Animal Health
5.6.1 Future developments
5.7 Hoechst Roussel Vet
5.7.1 Fenbendazole
5.7.2 Other antiparasitics
5.7.3 Future developments
5.7.4 Biotech Australia
5.8 Virbac
5.8.1 Future developments
5.9 Important generic companies
5.9.1 Phoenix Scientific
5.9.2 Ancare

REFERENCES AND FURTHER READING
PRODUCT INDEX

LIST OF TABLES
Table 1.1 Common cattle endoparasites
Table 1.2 Common cattle ectoparasites
Table 1.3 Common sheep and goat endoparasites
Table 1.4 Common sheep and goat ectoparasites
Table 1.5 Common pig endoparasites
Table 1.6 Common pig ectoparasites
Table 1.7 Common poultry endoparasites
Table 1.8 Common poultry ectoparasites
Table 1.9 Common horse endoparasites
Table 1.10 Common horse ectoparasites
Table 1.11 Common dog endoparasites
Table 1.12 Common cat endoparasites
Table 1.13 Common dog and cat ectoparasites
Table 1.14 Important endoparasites of fish
Table 1.15 Significant ectoparasites of fish
Table 2.1 Ectoparasitic product classes
Table 2.2 Endoparasitic product classes
Table 2.3 Endectocides
Table 2.4 Major ionophore anticoccidials
Table 2.5 Major chemical anticoccidials
Table 2.6 Commercially available vaccines
Table 2.7 Important generic manufacturers
Table 3.1 Antiparasitic research projects
Table 3.2 Vaccine research projects
Table 3.3 Current research projects using alternative strategies
Table 4.1 World animal health and nutrition market, 1997-1998 ($ million)
Table 4.2 Major national antiparasitics markets
Table 4.3 US antiparasitics market, 1998 ($ million)
Table 4.4 US livestock numbers (thousands)
Table 4.5 Brazilian livestock numbers (thousands)
Table 4.6 French livestock numbers (thousands)
Table 4.7 UK livestock numbers (thousands)
Table 4.8 Australian livestock numbers (thousands)
Table 4.9 Japanese animal health sales 1996-1998, estimated change from 1997-1998
(� million)
Table 4.10 Japanese veterinary antiparasitic sales in 1995-1997, estimated changes from 1996-1997 (� million)
Table 4.11 Top-selling heartworm preventatives in Japan, 1998
Table 4.12 Top-selling flea products in Japan, 1998
Table 4.13 Japanese livestock numbers, 1997-1998 (million)
Table 4.14 Top-selling endectocides in Japan, 1998
Table 4.15 Top-selling feed additive coccidiostats in Japan, 1998
Table 4.16 Argentinean livestock numbers, in 1997-1999 (thousand)
Table 4.17 South African livestock numbers, 1997-1999 (thousand)
Table 4.18 Chinese livestock numbers, in 1997-1999 (thousand)
Table 5.1 Merial's antiparasitic portfolio, 1998
Table 5.2 Pfizer's antiparasitics portfolio, 1998
Table 5.3 Bayer's antiparasitics portfolio, 1998
Table 5.4 Fort Dodge's acquisitions
Table 5.5 Fort Dodge's antiparasitics portfolio
Table 5.6 Novartis' antiparasitic products
Table 5.7 Schering-Plough Animal Health's antiparasitics products
Table 5.8 Hoechst Roussel Vet's antiparasitics
Table 5.9 Virbac's antiparasitics
Table 5.10 Phoenix's antiparasitics portfolio
Table 5.11 Ancare's antiparasitics portfolio

LIST OF FIGURES
Figure 4.1 World animal health and nutrition market by region, 1998
Figure 4.2 Global antiparasitics market, 1997-1998
Figure 4.3 Brazilian animal health market by product sector
Figure 4.4 Brazilian animal health sales by species
Figure 4.5 French animal health sales by market share, 1998
Figure 4.6 The UK animal health market, 1998
Figure 4.7 The UK antiparasitics market, 1998
Figure 4.8 Australian antiparasitics market, 1998
Figure 4.9 Argentinean antiparasitics market by sector, 1996
Figure 4.10 South African animal health sales, in 1997
Figure 5.1 Merial's sales by product group
Figure 5.2 Total Dectomax sales
Figure 5.3 HR Vet's sales by product sector, 1998

EXECUTIVE SUMMARY
The antiparasitics market has been the growth sector of the 1990s for the animal health industry. Since 1990, the antiparasitics market has more than doubled, but the major growth has been concentrated into the last 4-5 years. In 1995, sales of antiparasitic products represented just over one-fifth of the world animal health market. By 1998, this had increased to around one-quarter of the $17.9 billion animal health market.

Much of this growth is being driven by a handful of new antiparasitics for pets. The trend started when new heartworm and other endoparasitic products came onto the market in the 1980s, but in the mid-1990s the sector really grew when novel flea products were launched, accompanied by a major direct-to-consumer advertising campaign unprecedented in the animal health industry. Two of the three top-selling flea products came from chemical classes not previously used in animal health.

The new products have proved to be very efficacious, easy and convenient to use, with a wide safety margin. For these reasons the pet antiparasitics market continues to grow and has shown no signs of slowing. Some of the more successful antiparasitics have given companies a considerable boost in market share. Due to one or two very successful products, companies such as Bayer and Novartis have very rapidly become leaders in their chosen markets. Recent consolidation in the industry has also given several animal health companies a much stronger presence in the antiparasitics market.

The boom in the pet sector has demonstrated that pet owners are open to novel ideas, and unlike livestock producers, are willing to spend money on their pet's healthcare regardless of economic conditions. Thus, the race is on to develop the next blockbuster and new pet antiparasitics are in the research and development pipeline of several companies. There has also been a growing interest in research into vaccines for flea, tick and heartworm control, which are likely to be very profitable for their developers.

The livestock sector still dominates the antiparasitics market, and the 1990s are being marked by an expansion of the endectocide market, including the launch of a new endectocide - Merial's Ivomec Eprinex (eprinomectin). This has raised the stakes in an already very competitive environment. Meanwhile, many older products that characterise the antiparasitics market are becoming subject to heavy generic competition. The antiparasitics sector has been singled out as a major growth area for generics. Companies have had to become more and more inventive in their strategies for defending market share. An important strategy in the livestock antiparasitics sector has been the development of new delivery methods for products that have come off patent. The aim is to either gain new patent protection or to outsmart the generic manufacturers in terms of the technology, but the ploy is not always successful.

The livestock industry is becoming very troubled by the upsurge in parasitic resistance to drugs. Relatively few chemical classes show activity against parasites, which has meant that resistance has emerged rapidly, and producers have been left with a limited choice of products. This has led to a high demand for new products and for alternative methods of parasite control that do not rely on chemicals. Several livestock vaccines are currently being developed to meet the demand, and other alternative methods, such as breeding for resistance and biological control agents, are becoming available.

This report examines the major parasitic diseases affecting both pets and livestock, with particular reference to the economically most significant livestock diseases and the most common diseases of pets. It describes the main antiparasitic products currently on the market, including endoparasitics, ectoparasitics, endectocides, anticoccidials and vaccines, and the most commonly used drug delivery methods. An analysis is also given of the generics market and the problem of parasitic resistance.

The latest and most important research projects currently underway are described, including new antiparasitics, vaccines and alternative methods for parasite control.

The report also outlines the global antiparasitics market and future prospects of this fast-growing sector. Detailed analysis is given of the key national markets, looking at the importance and size of the antiparasitics market in each country and the major factors affecting the market. The leading companies in the sector are profiled, including details of their antiparasitics portfolio and future developments. Two generic companies that have a significant presence in the antiparasitics market are also discussed.